Johns Hopkins Medicine (JHM) and Premier, Inc. (NASDAQ: PINC) have agreed to collaborate on the development of innovative clinical and operational models designed to improve healthcare quality, safety and value, as well as impact overall wellness.
The five-year agreement combines expertise and assets from JHM—among the world’s leading academic medical centers—and Premier’s industry-leading performance improvement analytics and services in order to jointly develop and implement:
- Educational and research projects that focus on areas of strategic importance to members of the Premier alliance;
- Clinical and other prospective research that leverages the Johns Hopkins Institutional Clinical and Translational Research program; and
- Broad, evidence-based analytical healthcare solutions and services that leverage data from Premier’s integrated technology platform PremierConnect®.
In May of 2011, Johns Hopkins Medicine and Walgreens entered into a wide-ranging agreement designed to promote collaboration on population-based research and to jointly review and develop protocols to improve outcomes of patients with chronic diseases. In addition, JHM and Walgreens will together explore the development of new models for improving care for individuals.
Most recently, JHM and Walgreens has expanded their unique collaboration even further through the creation of a jointly owned Walgreens “Well Experience” store, located adjacent to the Johns Hopkins East Baltimore medical campus. The Walgreens store will odder new health and wellness programs for students and staff, as well as residents of the surrounding community.
Johns Hopkins Medicine and Healthways have had a decade long relationship focused on integrating evidenced-based practices into scalable programs to improve population health.
Most recently, Healthways, a global health and well-being improvement company, have developed Innergy™, a commercially available version of the call center-directed weight-loss program pioneered and studied by Lawrence J. Appel, M.D., a professor of medicine at the Johns Hopkins University School of Medicine. The results of the study were published in November in the New England Journal of Medicine. Under the agreement between Hopkins and Healthways, Hopkins will advise Healthways on the design and implementation of Innergy, continuously evaluate the program, and oversee future enhancements. Several Hopkins faculty members will also serve on Innergy’s scientific advisory board.
Johns Hopkins Medicine, a shared investment partner in Sleep Services of America Inc. (SSA) for the past ten years, purchased GE Healthcare/Vital Signs, Inc.’s investment stake in SSA effective July 1, 2013. This transaction resulted in Johns Hopkins Medicine becoming the majority and principal shareholder. This allows Johns Hopkins Medicine to support a core service in the area of sleep medicine supporting its tripartite mission of research, teaching and patient care.
Hospital at Home® is an innovative model that provides hospital-level care in a patient's home as a full substitute for acute hospital care. The program was developed by researchers at the Johns Hopkins Schools of Medicine and Public Health and successfully tested in a National Demonstration and Evaluation Study.
Researchers and physicians at Johns Hopkins University are teaming with IMEC, a Belgian based nanoelectronics R&D center to advance silicon applications in healthcare. The initial focus of the collaboration is the development of a low cost, point-of-care device to enable a broad range of clinical tests that will aid in disease surveillance and diagnosis, clinical trials, and disease management. The two organizations plan to forge strategic ties with additional collaborators in the healthcare and technology sectors.